Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy
ConclusionAnti-CD20 monoclonal antibody therapy is associated with high COVID-19 mortality and with a phenotype consistent with prolonged viral pneumonia. Our study provides rationale for retesting of immunocompromised patients with prolonged COVID-19 symptoms and considering antiviral therapy.
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | COVID-19 | Finland Health | Infectious Diseases | Microbiology | Pneumonia | SARS | Study